News
As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...
Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback